rs35908749
Positions:
Variant summary
Our verdict is Benign. Variant got -15 ACMG points: 0P and 15B. BP4_ModerateBP6_Very_StrongBP7BS1
The NM_000249.4(MLH1):c.702G>A(p.Glu234=) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000453 in 1,604,218 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★★).
Frequency
Genomes: 𝑓 0.00042 ( 0 hom., cov: 32)
Exomes 𝑓: 0.00046 ( 1 hom. )
Consequence
MLH1
NM_000249.4 synonymous
NM_000249.4 synonymous
Scores
2
Clinical Significance
Conservation
PhyloP100: 0.629
Genes affected
MLH1 (HGNC:7127): (mutL homolog 1) The protein encoded by this gene can heterodimerize with mismatch repair endonuclease PMS2 to form MutL alpha, part of the DNA mismatch repair system. When MutL alpha is bound by MutS beta and some accessory proteins, the PMS2 subunit of MutL alpha introduces a single-strand break near DNA mismatches, providing an entry point for exonuclease degradation. The encoded protein is also involved in DNA damage signaling and can heterodimerize with DNA mismatch repair protein MLH3 to form MutL gamma, which is involved in meiosis. This gene was identified as a locus frequently mutated in hereditary nonpolyposis colon cancer (HNPCC). [provided by RefSeq, Aug 2017]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -15 ACMG points.
BP4
?
Computational evidence support a benign effect (BayesDel_noAF=-0.42).
BP6
?
Variant 3-37014456-G-A is Benign according to our data. Variant chr3-37014456-G-A is described in ClinVar as [Likely_benign]. Clinvar id is 36558.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr3-37014456-G-A is described in Lovd as [Likely_benign].
BP7
?
Synonymous conserved (PhyloP=0.629 with no splicing effect.
BS1
?
Variant frequency is greater than expected in population amr. gnomad4_exome allele frequency = 0.000456 (662/1451944) while in subpopulation AMR AF= 0.000805 (36/44696). AF 95% confidence interval is 0.000598. There are 1 homozygotes in gnomad4_exome. There are 324 alleles in male gnomad4_exome subpopulation. Median coverage is 28. This position pass quality control queck.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
MLH1 | NM_000249.4 | c.702G>A | p.Glu234= | synonymous_variant | 9/19 | ENST00000231790.8 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
MLH1 | ENST00000231790.8 | c.702G>A | p.Glu234= | synonymous_variant | 9/19 | 1 | NM_000249.4 | P1 |
Frequencies
GnomAD3 genomes ? AF: 0.000421 AC: 64AN: 152156Hom.: 0 Cov.: 32
GnomAD3 genomes
?
AF:
AC:
64
AN:
152156
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000426 AC: 107AN: 251146Hom.: 0 AF XY: 0.000398 AC XY: 54AN XY: 135750
GnomAD3 exomes
AF:
AC:
107
AN:
251146
Hom.:
AF XY:
AC XY:
54
AN XY:
135750
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000456 AC: 662AN: 1451944Hom.: 1 Cov.: 28 AF XY: 0.000448 AC XY: 324AN XY: 723078
GnomAD4 exome
AF:
AC:
662
AN:
1451944
Hom.:
Cov.:
28
AF XY:
AC XY:
324
AN XY:
723078
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome ? AF: 0.000420 AC: 64AN: 152274Hom.: 0 Cov.: 32 AF XY: 0.000430 AC XY: 32AN XY: 74444
GnomAD4 genome
?
AF:
AC:
64
AN:
152274
Hom.:
Cov.:
32
AF XY:
AC XY:
32
AN XY:
74444
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Likely benign
Submissions summary: Uncertain:1Benign:18
Revision: reviewed by expert panel
LINK: link
Submissions by phenotype
Hereditary cancer-predisposing syndrome Benign:5
Likely benign, no assertion criteria provided | clinical testing | True Health Diagnostics | Oct 04, 2018 | - - |
Benign, criteria provided, single submitter | curation | Sema4, Sema4 | Oct 20, 2020 | - - |
Likely benign, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Apr 01, 2015 | - - |
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Aug 01, 2014 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Benign, criteria provided, single submitter | clinical testing | Institute for Biomarker Research, Medical Diagnostic Laboratories, L.L.C. | Nov 06, 2023 | - - |
not provided Benign:4
Likely benign, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Jul 01, 2024 | MLH1: BP4, BP7 - |
Likely benign, no assertion criteria provided | clinical testing | Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ | - | - - |
Likely benign, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | May 03, 2016 | Variant summary: This synonymous variant is located 25 nts downstream of intron-exon junction in coding region. 3/5 splice-site tools predict the variant not to have effect on splicing and two independent functional studies showed that this variant does not have effect on normal splicing (Borras et al 2012 and Thompson et al 2013). This variant has been reported in multiple HNPCC patients mostly of European origin, albeit some of them did not fulfilling Amsterdam criteria for HNPCC diagnosis. In one patient, another variant that could explain the phenotype was also detected. The variant was found at a frequency of 0.0392% in the general population (47/119650 chromosomes), clustered mainly in the population of European origin with no homozygous occurrence. This frequency in general population is lower than the maximal expected allele frequency (0.07%) for pathogenic MLH1 variant. Lastly, reputable databases and diagnostic centers classify the variant as likely benign/benign/neutral. Taken together, this variant has been classified as likely benign. - |
Likely benign, no assertion criteria provided | clinical testing | Clinical Genetics, Academic Medical Center | - | - - |
not specified Benign:3
Benign, criteria provided, single submitter | clinical testing | GeneDx | Jan 23, 2014 | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. - |
Likely benign, no assertion criteria provided | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | - | - - |
Likely benign, criteria provided, single submitter | clinical testing | Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital | Aug 15, 2023 | - - |
Colorectal cancer, hereditary nonpolyposis, type 2 Uncertain:1Benign:1
Uncertain significance, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 27, 2017 | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. However, the evidence from the literature, in combination with allele frequency data from public databases where available, was not sufficient to rule this variant in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. - |
Likely benign, criteria provided, single submitter | clinical testing | Mendelics | May 28, 2019 | - - |
Lynch syndrome Benign:2
Likely benign, reviewed by expert panel | research | International Society for Gastrointestinal Hereditary Tumours (InSiGHT) | Sep 05, 2013 | Synonymous substitution with no splicing aberration, treated with NMD inhibitor - |
Likely benign, criteria provided, single submitter | clinical testing | All of Us Research Program, National Institutes of Health | Feb 05, 2024 | - - |
Breast and/or ovarian cancer Benign:1
Likely benign, criteria provided, single submitter | clinical testing | CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario | Jun 24, 2021 | - - |
Hereditary nonpolyposis colorectal neoplasms Benign:1
Benign, criteria provided, single submitter | clinical testing | Invitae | Jan 31, 2024 | - - |
Malignant tumor of breast Benign:1
Likely benign, no assertion criteria provided | clinical testing | Department of Pathology and Laboratory Medicine, Sinai Health System | - | The MLH1 p.Glu234Glu variant was identified in 5 of 1752 proband chromosomes (frequency: 0.003) from individuals or families with colon cancer or hereditary non-polyposis colorectal cancer and was not identified in 604 control chromosomes from healthy individuals (Borras 2012, Curia 1999, Grabowski 2004, Caldes 2002). The variant was also identified the following databases: dbSNP (ID: rs35908749) as “With Likely benign allele”, ClinVar (classified as benign 2x by GeneDx and Invitae; and classified as likely benign 4x by InSiGHT, Ambry Genetics, Color Genomics, Laboratory Corporation of America), Clinvitae (classified 2x as benign by GeneDx and Invitae; 4x as likely benign by Ambry Genetics, Color Genomics, InSiGHT, Laboratory Corporation of America), UMD-LSDB (observed 8x), Insight Colon Cancer Gene Variant Database (5x pathogenicity unknown, 1x probably no pathogenicity), Mismatch Repair Genes Variant Database, Insight Hereditary Tumors Database (6 references, all classified as “probably does not affect function”). The variant was not identified in COGR, COSMIC, MutDB, or the Zhejiang Colon Cancer Databases. The variant was identified in control databases in 110 of 276966 chromosomes at a frequency of 0.0004 in the following populations: Latino in 27 of 34398 chromosomes (freq. 0.0008); European non-Finnish in 67 of 126622 chromosomes (freq. 0.0005); South Asian in 10 of 30766 chromosomes (freq. 0.0003); population listed as Other in 2 of 6458 chromosomes (freq. 0.0003); and African in 3 of 23948 chromosomes (freq. 0.0001) increasing the likelihood this could be a low frequency benign variant (Genome Aggregation Consortium Feb 27, 2017). This variant was identified in a patient with endometrial cancer whose family meets Amsterdam criteria and was negative for MLH1 by IHC, however this variant did not affect mRNA processing or stability and the authors conclude that the variant is likely neutral (Borras 2012). Additionally, this patient was found to have two other MLH1 missense variants which resulted in exon 9 skipping and a truncated protein. This variant was also observed in a patient with colon cancer and resulted in a modest germline transcript unbalance in a primer extension assay (Curia 1999). The p.Glu234Glu variant is not expected to have clinical significance because it does not result in a change of amino acid. Three of five in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) predict a greater than 10% difference in splicing however this information is not very predictive of pathogenicity. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time although we would lean towards a more benign role for this variant. This variant is classified as likely benign. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at